SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging following a blowout earnings report and raised guidance that highlighted strong momentum in data center and AI-driven demand. The community is actively debating whether this explosive rally marks the start of a generational growth phase or a speculative bubble, with many traders discussing potential short squeezes and aggressive price targets.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing renewed bullish sentiment as the stock recovers from lows, fueled by evidence that its oral Wegovy prescriptions are outpacing Eli Lilly's recent weight-loss pill launch and a favorable ruling by the FDA regarding compounded alternatives. Investors are increasingly optimistic that Novos established distribution, competitive pricing, and upcoming Medicare coverage will drive a strong rebound, with many pointing to a compelling valuation as the stock re-rates from recent sell-offs.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging in after-hours trading as investors prioritize the company's significant margin recovery and upbeat forward guidance over a reported revenue miss. The community is actively debating the stock's massive short interest and potential for a squeeze, with many long-term holders pointing to its low valuation relative to AI peers as a catalyst for a sustained rerating.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing a massive parabolic rally fueled by a structural supercycle in AI-driven memory demand and a persistent supply shortage. The community remains deeply divided, with bulls pointing to fundamental re-rating and order growth while bears express significant concern over speculative euphoria and the sustainability of the current price levels.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing massive bullish momentum driven by insatiable AI-driven demand for memory chips and data center storage, leading to intense speculative trading and record-setting options volume. Community sentiment is overwhelmingly bullish, with many investors viewing the stock as a long-term leader in the AI infrastructure supercycle despite its significant year-to-date appreciation.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is rallying following a massive $1.1 billion AI colocation agreement with Cerebras Systems, fueling community optimism about its role as a validated data center infrastructure provider. While bullish traders are focused on the long-term revenue visibility and upcoming Cerebras IPO as key catalysts, others remain cautious of high volatility and potential dilution.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as investors focus on its privacy narrative and recent integration into major trading platforms, sparking community debates about its potential as a long-term store of value. Sentiment remains highly polarized, with many users speculating on supply dynamics and institutional interest while others caution against volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Investors are closely monitoring ImmunityBio as the stock builds momentum ahead of upcoming earnings and key data presentations, with community discussion centered on potential global expansion and intense frustration toward the high short interest. Speculation is high that recent executive communications and international travel signal a major catalyst or deal that could challenge the current regulatory gridlock in the U.S.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention following positive Phase 2 trial results for its lead skin disease drug, with the community closely tracking the company's subsequent public offering and the potential for a short squeeze. Despite concerns regarding dilution, investors remain focused on the clinical progress and the possibility of further price momentum as the company advances its pipeline.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Transmedics Group is attracting significant attention as investors react to robust flight data and strategic infrastructure expansion, fueling confidence in its long-term market dominance. The community is actively discussing the stock's resilience, recent insider buying, and the potential for a breakout as the company scales its unique organ preservation technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

Nasdaq Turns Positive in 2025: ETFs to Ride the Rally

Logitech International S.A. (LOGI) division Streamlabs announced substantial enhancements to its AI-powered streaming assistant on Tuesday, ahead of its full-scale launch, which is anticipated later in 2025.&nbsp;The latest version of the Streamlabs Intelligent Streaming Agent was showcased at Computex, highlighting a leap in live content creation and audience engagement capabilities for streamers.The upgraded platform integrates advanced systems developed by NVIDIA Corp. (NVDA) and the narrative-focused AI engine Inworld AI.&nbsp;Designed to respond instantly to live gameplay and viewer engagement, the system allows for a more interactive and immersive streaming experience.The latest capabilities enable content creators to streamline elements of their livestreams using real-time, context-sensitive triggers, executing tasks like switching scenes, playing sound effects, or having the avatar speak tailored messages, eliminating the need for manual intervention.The refined Streaming Agent empowers creators with advanced avatar customization, letting them tailor personality, voice, and expressions using NVIDIA's digital human tools and Inworld AI.&nbsp;It also acts as a real-time assistant, offering technical guidance and creative support drawn from a knowledge base, helping streamers of all skill levels navigate live broadcasts more effectively.&nbsp;“Together with NVIDIA and Inworld AI, we’re advancing interactive technology to help streamers engage with their audiences in new and creative ways,” said Head of Streamlabs, Ashray Urs.&nbsp;“The tools we’re unveiling today represent an entirely new era of digital storytelling, and the new demo at Computex is a crucial step closer to bringing these solutions to market at scale.”The upgrade also improves how streamers connect with their audiences through chat.&nbsp;The assistant can now generate quick recaps for viewers who join late and launch interactive polls that let the audience influence decisions mid-stream.&nbsp;On Stocktwits, sentiment around Logitech improved from ‘bearish’ to ‘neutral’.<figure class="image"><img style="aspect-ratio:632/75;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_20_071509_png_fb3b91ea6e.webp" alt="Screenshot 2025-05-20 071509.png" width="632" height="75"><figcaption>LOGI's Sentiment Meter and Message Volume as of 07.30 a.m. ET on May 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/LOGI">Logitech</a> stock has&nbsp;gained 5% in 2025 but shed 3.7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-india-ambitions-gain-momentun-with-foxconn-s-1.5-b-investment/ch0doKSRb8x">Apple’s India Ambitions Gain Momentum As Foxconn Invests $1.5B In Local iPhone Assembly Arm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Logitech company logo is seen displayed on a smartphone screen.

Logitech’s Streaming Agent Gets Smarter, More Personal: Retail Sentiment Improves 

The upgraded AI assistant provides real-time automation, avatar customization, and interactive tools to boost livestream production and audience engagement.

Equity

The upgraded AI assistant provides real-time automation, avatar customization, and interactive tools to boost livestream production and audience engagement.


Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a settlement payment with the National Institutes of Health, drawing a cautious response from retail investors.The payment reportedly comprises $750 million as a settlement for claimed royalties during calendar years 2020-2023, and $41.5 million consideration for the NIH towards an amended and restated license agreement, dated December 20.BioNTech, a clinical-stage biotechnology company, focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.BioNTech had been in discussions with the National Institutes of Health concerning royalties and other amounts allegedly owed on certain sales along with its collaboration partner Pfizer in connection to COVID-19 vaccine, the Fly.com reported.Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.<stembedurl>https://stocktwits.com/taxplanr/message/597983247</stembedurl> <stembedurl>https://stocktwits.com/taxplanr/message/597861544</stembedurl> &nbsp;The Fly.com report said the company's execution of the settlement agreement wasn’t an admission of liability as the company denied it had any legal liabilities or was in violation of any laws.NIH has reportedly agreed to consider any alleged noncompliance under the amended license agreement to be resolved for the period up to and including January 1, 2024, including any claimed historical royalty payments allegedly owed by the company prior to January 1, 2024.In parallel, BioNTech and the NIH also entered into the amended license agreement that provides a “framework” for a license for use in combination products including the COVID-19 vaccine used in combination with other active pharmaceutical ingredients.The settlement agreement requires Pfizer to reimburse BioNTech for $364.5 million of the claimed royalties paid to the NIH for 2020-2023 sales, the report added.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious

Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

Chinese search engine and artificial intelligence (AI) company Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) reported sub-par third-quarter earnings amid weakness in its core online marketing business.Beijing, China-based Baidu reported third-quarter non-GAAP earnings per ADS of 16.60 yuan or $2.37, marking a 19% year-on-year (YoY) decline and a 21% sequential drop. Analysts, on average, estimated 17.90 yuan per ADS for the quarter, according to Yahoo Finance.Total revenue slipped 3% YoY and 1% sequentially to 33.56 billion yuan or $4.78 billion, slightly ahead of the 33.43-billion-yuan consensus estimate polled by LSEG, according to Reuters.Baidu Core revenue was flat YoY to 26.5 billion yuan, with online marketing revenue slipping 4% to 18.8 billion yuan. The decline was offset by a 12% increase in online non-marketing revenue, driven by the AI Cloud business.Revenue from iQIYI, Baidu’s&nbsp;Chinese subscription video on-demand over-the-top streaming service, fell 10% to 7.2 billion yuan.Commenting on the quarterly performance, Robin Li, CEO of Baidu said, "Core's flattish third quarter top line reflected the ongoing weakness in our online marketing business, offset by the growth of our AI Cloud business."Li, however, said Baidu’s AI&nbsp; capabilities are gaining broader market recognition, as evidenced by increasing adoption of the ERNIE humanoid robot.&nbsp;The company’s robotaxi service “Apollo Go” has achieved another milestone with its sixth-generation autonomous vehicle RT6, which is now operating on public roads across multiple Chinese cities, he added.Rides provided by Apollo Go's fully driverless vehicles accounted for over 70% of total rides nationwide in the third quarter, rising further to 80% in October."Despite the near-term pressures, we remain steadfast in our AI-focused strategy and are confident in our long-term trajectory," Li said.Interim CFO Junjie He said core operating margins remained stable as the company managed to further optimize costs and realized cost efficiencies between business units.<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:637/188;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_bf502ab31c.png" alt="bidu-sentiment.png" width="637" height="188"></a><figcaption>NVDA sentiment and message volume November 21, 2024, as of 10:35 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward Baidu stock stayed 'bullish’ (61/100), with message volume spiking to 'extremely high.'Baiidu was among the top 10 trending stocks on Stocktwits on&nbsp;Thursday.Some retailers on&nbsp;the platform lamented over the company’s lack of shareholder return policy. Others said the stock is undervalued.Baidu's ADS listed on Nasdaq fell 6.98% to $80.69. It is down more than 27% so far this year amid the fundamental woes and general caution toward Chinese stocks.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-jensen-huang-weighs-in-on-tariff-threat/cJIT8NfRX1">Nvidia CEO Commits To Trump Policy Support, Reveals Strategy To Offset Tariff Challenges: Retail Stays Bullish</a>

Baidu said it remains steadfast in its AI-focused strategy and is confident in its long-term trajectory. 

Baidu Stock Pulls Back On Mixed Q3 Results: Retail Applauds Company’s Positive Long-Term Commentary

Baidu said the ongoing weakness in the online marketing business was offset by the growth of its AI Cloud business.

Trip.com Holdings Limited (<a class="mention" data-mention="$TCOM" data-symbol-id="TCOM" href="https://stocktwits.com/symbol/TCOM" target="_blank">$TCOM</a>), a one-stop travel platform, is scheduled to report its third-quarter results after the market closes on Monday.Shanghai, China-based Trip.com’s quarterly earnings per share (EPS) is widely expected to decline from $1.10 in 2023 to $0.96 in 2024. The consensus, however, models an increase in revenue from $1.93 billion to $2.18 billion.&nbsp;&nbsp;In the preceding quarter, Trip.com’s revenue climbed 14% year-over-year (YoY), with the company attributing the growth to strong travel demand, especially cross-border travel. Adjusted earnings before interest, taxes and depreciation climbed about 19%.On the second-quarter earnings call, co-founder and executive chair of the board Jianzhang Liang said, "We are committed to harnessing the power of AI and unlocking its full potential, ensuring we deliver exceptional value and continuous innovation to meet the evolving needs of our customers."In June, the company launched its AI-powered 2024 Trip.Best Global and Asia 100 lists which are based on real user reviews and year-round sales popularity.&nbsp;CEO Jie Sun highlighted the resilience of the Chinese travel market and said the travel market will see robust growth following a strong start in 2024.Data from Statista&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statista.com/statistics/1215457/most-visited-travel-and-tourism-websites-worldwide/">showed</a> that Trip.com was the fourth-most visited website worldwide in October, with 100.83 million visitors compared to Booking Holdings, Inc.’s (<a class="mention" data-mention="$BKNG" data-symbol-id="BKNG" href="https://stocktwits.com/symbol/BKNG" target="_blank">$BKNG</a>) 528.03 millionThe anticipated economic recovery in China on the back of copious stimuli from the government and the central bank should bode well for the company.Last week, BofA raised the price target for Trip.com stock from $56 to $67, assuming a 20-30% rise in non-GAAP profit for the 2024-25 period due to efficiency measures implemented by the company and its strong operating leverage.Ahead of it, Mizuho Securities bumped up the price target from $65 to $78, citing China’s stimulus policies. Despite a mixed outlook due to tariff threats and the structural challenges faced by the Chinese economy, the firm remained positive about outbound travel demand in China.&nbsp;Trip.com shares have rallied over 65% for the year-to-date period. They ended Friday’s session down 0.73% at $59.49.Commenting on the Stocktwits platform, an options trader said Trip.com shares have notable relative strength among Chinese ADRs.<stembedurl>https://stocktwits.com/ivanhoff/message/591135201</stembedurl>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-urban-air-mobility-company-ehang-is-due-to-report-q3-2024-results/cJ4HqbIRQc">Chinese Flying Taxi Company EHang Expected To Report Strong Revenue Growth In Q3: Retail Sentiment Soars</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trip.com shares have gained over 65% for the year. 

Trip.com Analysts Optimistic Amid Robust Travel Trends In China As Stock Looks To Extend Strong Gains For Year 

Mizuho’s optimism regarding Trip.com is premised on strong outbound travel trends in China despite the domestic economy’s structural challenges and the looming tariff threat.

Invesco Exchange-Traded Fund Trust II - Invesco NASDAQ Next Gen 100 ETF

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$41.13
Prev Close	$40.70
Open	$40.84
Dividend Yield	N/A
50-Day Moving Average	$38.22
Beta	N/A
Avg. Volume	166,446.92
PE Ratio	N/A

52-Week High	$41.55
52-Week Low	$29.22
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

QQQJ
Invesco NASDAQ Next Gen 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQQJ News

QQQJInvesco NASDAQ Next Gen 100 ETF